Proactive news headlines: Deltic Energy PLC, CMC Markets PLC, Allergy

 () revealed it has significantly expanded its footprint in the Southern and Central North Sea, landing six awards in the UK government’s latest offshore licensing round The company, in a statement, announced it had been provisionally awarded six licences, covering twelve full and part blocks, which span a total of 2,155.5 square kilometres. In a separate statement, Deltic’s interim results highlighted a strong balance sheet, with £12.8mln of cash at the end of June 2020, and confirmed that its North Sea venture with Shell remains on-track. The partners are committed to meeting the licence terms for the P2252 asset, which primarily includes the Pensacola prospect, and that would see a contingent well commitment become firm by December 2020. A Pensacola well could come as soon as next year.

() has lifted market guidance again, with current year net operating income expected to be ahead of the current market consensus. The trading platform operator issued a trading update covering the period since July 1 in which it said the consistently strong performance across the business had continued, with the net income operating income run rate running only slightly below the preceding three months – the first quarter of CMC’s fiscal year – when volatility was running high as a result of uncertainty caused by the spread of the coronavirus (COVID-19). Client income has continued to exceed the corresponding period of 2019 while client income retention has remained well above the guidance of more than 80%. The stockbroking business also continues to perform strongly.

() is expanding its licensing agreement with vaccine groups Saiba and DeepVax in a move that will take it into oncology. The move builds on a collaboration in the area of virus-like particle (VLP) technology that has seen the UK group develop a peanut allergy candidate which has shown early promise. The plan is to expand the tie-up to target solid cancer tumours, atopic dermatitis, asthma, and psoriasis.

() said it has agreed distribution deals with three leading global broadcasters, alongside its partner Abu Dhabi Motorsport Management (ADMM), for the new V10 R-League virtual racing competition, the first championship in a global racing series partnership between the two firms. Under the agreements, the V10 R-League will be available on BT Sport, ESPN and STARZPLAY Arabia, while highlights will be broadcast across team and talent channels in a distribution plan covering both broadcast and digital formats. BT Sport and STARZPLAY Arabia have signed multi-year commercial agreements for exclusive rights in the UK & Ireland and the Middle East and North Africa (MENA) regions respectively, while ESPN’s agreement means season one and two of the V10 R-League will be broadcast in the US and made available in Canada, Latin America, the Netherlands, the Caribbean and Oceania.

PLC () has highlighted progress in the development of a coronavirus test by its investee company Paraytec and the University of Sheffield. The investment group said having previously completed work packages relating to the construction of a viral mimic and the capture SYSTEM for the test, Paraytec’s development of a signal generation module, which contains a synthetic coronavirus binding protein molecule bonded to fluorescent nanospheres, has now been completed. Meanwhile, Braveheart said work has been initiated and continues to progress on building an optical detection system, which is used to detect and quantify the fluorescent nanospheres that bind the CAPTURE Module in the presence of the virus.

Holdings PLC () said an approach to managing lung cancer that uses the EarlyCDT Lung test pioneered by the group has been deemed “highly cost-effective” by healthcare economists. The study, led by academics from Leeds University, assessed the treatment of people with indeterminate pulmonary nodules (IPNs). It looked at the deployment of the £70 Oncimmune blood test in…